Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 4 Hodgkin Disease 3 Triple Negative Breast Neoplasms 2 Rhabdomyosarcoma 2 Recurrence 2 Neoplasms 2 Advanced Breast Cancer 2 Neoplasm Metastasis 1 NSCLC 1 Metastatic HER2-positive Breast Cancer 1 Lung Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2-negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Adenocarcinoma 1

Interventions

trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 liposomal doxorubicin 1 eribulin 1 Vinorelbine 1 Paclitaxel 1 Gemcitabine 1 Epirubicin 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HER2-negative Breast Cancer × Vinorelbine × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡